*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Summary Sentence: Nathan Chiappa and Nick Willett presenting
Full Summary: The Graduate and Post-Doc (GaP) Seminar Series is a weekly event of research presentations by two graduate students or post-docs conducting bio-related research. The series is organized and sponsored by the Parker H. Petit Institute for Bioengineering and Bioscience (IBB) with additional support from the Wallace H. Coulter Department of Biomedical Engineering. It is held every Wednesday at 12:00pm in IBB 1128 and refreshments are provided. If your research group or department would like to present at future seminars, please contact Manu Platt, PhD.
GaP Seminar Series
Nick Willett, PhD
Nathan ChiappaNathan Chiappa - Advisor, Edward Botchwey, PhD
"Computational Modeling of Modulation of Sphingolipid Metabolism by FTY720"
Sphingolipids play important physiological and pathological roles. Sphingolipid levels are controlled by a complex metabolic network. We have constructed a computational model of this network which allows for investigation of the effects of the immunomodulator FTY720 on sphingolipid metabolism in different cell types. The model results have important implications for potential therapeutic modulation of sphingolipid metabolism in many diseases.
Nick Willett, PhD - Advisor, Robert Guldberg, PhD
"Quantitative Screening of Novel Therapeutics to Treat Osteoarthritis"
Osteoarthritis (OA) is a large clinical burden with no interventions to modify disease progression. We evaluated two prospective disease modifying treatments in a surgically induced rat model of OA. This study demonstrated that EPIC-µCT has the sensitivity to evaluate the efficacy of OA therapies. The overall outcomes of this study will have a direct impact on the throughput for screening novel OA therapeutics in pre-clinical models.
